Contact
Whether you’re a veterinarian, veterinary team member, horse owner, or partner, we’re here to help with product questions, support, and next steps.
Our peer-reviewed trial in Frontiers in Veterinary Science is live, the largest controlled trial of its kind in equine regenerative medicine.
Having trouble viewing the form? Click here to open in a new window.
Pharmacovigilance
If you are a veterinarian or owner and have observed an unexpected reaction or outcome following the use of equicenta® CTM, we want to hear about it. Pharmacovigilance is built into our quality system, and your reports help us continue to evaluate the safety profile of our product in clinical use.
How to report:
Your report will be acknowledged within one business day and routed to the appropriate clinical reviewer.
Clinical Case Studies
Veterinarians interested in clinical case studies can contact our scientific team to learn how to participate. We can share the published data, study details, and what is involved in a case study opportunity.
Review the published data first: BMC Safety Study · Frontiers Clinical Study
Common questions from clinics, owners, and partners.
Now Published
In a published, open-label controlled trial (Bertone et al., 2026), a single injection of equicenta® CTM was associated with 2.72:1 odds of returning to prior performance. Injection reactions were reported after 3.4% of equicenta® CTM injections and 10.5% of standard-of-care injections.
Study limitations: open-label design; heterogeneous, clinician-selected comparator; funded by Equine Performance Labs.
For use by or on the order of a licensed veterinarian. Not for use in humans.
By submitting, you agree to receive occasional science and product updates from Equine Performance Labs. Unsubscribe anytime.
